|
Business Wire is a trusted partner to hundreds of Health, Medical,
Biotech and Pharmaceutical companies and organizations throughout
the world, delivering more news releases from more sources to more
destinations than any other service. For additional information visit WWW.BUSINESSWIRE.COM or email TRADESHOW@BUSINESSWIRE.COM |
 |
|
De Facto Communications is one of Europe's most successful public relations consultancies in life science, healthcare and clinical trials marketing. Headquartered in London, De Facto is part of Chime Communications plc and delivers award-winning, integrated communications programmes based on effective strategy, original thinking and attention-grabbing creativity. |
 |
| The Journal of Biolaw & Business Grow your business with The Journal of BioLaw & Business! The Journal of BioLaw & Business is the leading international publication established in 1997 to address emerging legal, business, scientific and regulatory issues impacting the growth of the biotechnology, life science and investment sectors. BioLaw's world-class expert advisory board, educational supporters and authors provide original substantive analyses, and valuable practical tools and guidance to biotechnology and life science executives, attorneys, biomedical researches, entrepreneurs, licensing and tech transfer specialists, investors and policy-makers. Special thematic BioLaw & Business Supplements (on topics such as licensing, intellectual property, bioinformatics, and venture financing) can also be ordered separately. On-line full text access is available to subscribers and member sites. Published quarterly, with topic-specific supplements
and electronic updates, BioLaw offers timely reporting, thoughtful
analysis, case studies and practical solutions to present issues
and future concerns in these emerging fields. It is designed for
those who want to stay ahead of rapidly changing innovations. BioLaw's
distinguished advisors and authors offer "real world"
perspectives and the practical tools necessary to meet the sectors'
unique challenges. |
 |
|
Richard Lewis Communications, Inc. and TS Communications Group, LLC, based in New York, have formed a strategic alliance to offer full service corporate and investor communications to therapeutically focused biotechnology companies in all stages of development. The combined synergy of the two companies leverages a deep understanding of our clients’ business strategies. Through our team of senior level counselors, we specialize in designing programs related to strategic planning, investor relations, public and media relations, business development, patient advocacy outreach, and clinical trials recruitment strategies and execution. Our strengths are combining our “hands-on” knowledge of drug development with concrete biotechnology and Wall Street experience – both on the client side and agency side. This unique combination enables us to provide our clients with more than 40 years of combined experience to develop a tactical communications program that addresses the unique needs of both private and public biotechnology companies seeking to increase their operational effectiveness. For more information about RLC, visit www.rlcinc.com or call Gregory Tiberend, EVP & COO, at 212-827-0020. For more information about TSCG, visit www.biotechirpr.com or call Tara Spiess, President, at 914-921-5900. |
 |